Form 4: Azitra CFO Norm Staskey Granted 15,015 Stock Options

Azitra, Inc.'s Chief Financial Officer, Norm Staskey, received a grant of 15,015 stock options with an exercise price of $0.2968, vesting over 36 months.

Summary

• Norm Staskey, Chief Financial Officer of Azitra, Inc. (AZTR), was granted 15,015 stock options.
• The options have an exercise price of $0.2968 per share.
• The transaction date for the grant was December 19, 2025.
• The options will vest with 25% on the date of issuance (December 19, 2025) and the remaining balance in equal monthly installments over the subsequent 36 months of continuous service.
• The expiration date for these stock options is December 19, 2035.

Sentiment

Score: 6

Explanation: The filing reports a routine executive compensation event (stock option grant) which is generally positive for aligning management incentives with shareholder interests, but does not contain new fundamental information to significantly alter the company's outlook.

Positives

• The grant of stock options aligns the Chief Financial Officer's interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedule encourages continuous service and commitment from a key executive.

Negatives

• Potential for future dilution if options are exercised, though this is a standard component of executive compensation.

Risks

• The value of the stock options is dependent on the future market price of Azitra, Inc. common stock, which is subject to market volatility and company performance.
• If the stock price does not rise above the exercise price of $0.2968, the options may expire worthless.

Future Outlook

This grant signifies a long-term incentive for the CFO, suggesting an expectation of continued service and contribution to the company's future performance over the vesting period.

Industry Context

Granting stock options to key executives like the Chief Financial Officer is a common practice across various industries, particularly in biotechnology and emerging growth companies, to attract, retain, and motivate talent by linking their compensation to the company's long-term success and shareholder value creation.

Comparison to Industry Standards

• The practice of granting stock options as part of executive compensation is a widely accepted industry standard, comparable to practices at companies like Moderna (MRNA) or BioNTech (BNTX) for their executives, albeit on a different scale.
• The vesting schedule, with an initial cliff and subsequent monthly installments over 36 months, is a common structure designed to ensure executive retention and align interests over a multi-year horizon, similar to equity compensation plans observed at many publicly traded technology and life sciences firms.

Corporate Governance

Related Party Transactions

• The grant of stock options to Norm Staskey, the Chief Financial Officer, constitutes a related party transaction as it involves an executive of the company.

Stakeholder Impact

• Shareholders: Minor potential future dilution upon exercise of options, but benefits from increased alignment of executive incentives with long-term shareholder value creation.
• Employees: May signal stability in executive leadership and a commitment to long-term growth, potentially boosting morale.
• Management: Provides a significant long-term incentive and compensation component, encouraging continued dedication and performance.

Next Steps

• Continued service by the Chief Financial Officer to fulfill vesting requirements.
• Potential future exercise of options by the CFO, subject to vesting and stock price performance.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event and does not provide new material information that would fundamentally alter the investment thesis for Azitra, Inc. While aligning management interests is positive, it's not a catalyst for a change in recommendation.

Keywords

Azitra, AZTR, Stock Options, Insider Transaction, Executive Compensation, Form 4, Norm Staskey, CFO, Equity Grant